Compare Abeona Therapeutics Inc (ABEO) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ARMOUR Residential REIT, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while ARMOUR Residential REIT, Inc. trades at $16.9 (market cap $2.11B). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 5.7× Abeona Therapeutics Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 16.96% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ARR | |
|---|---|---|
Market Cap | $373.32M | $2.11B |
Sector | Health | Financials |
52-Week High | $7.23 | $19.12 |
52-Week Low | $4.17 | $14.05 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 16.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARR trades at $16.98, down 0.88% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows a low P/E of 6.9 and P/B of 0.91, with strong net income margin of 95.99% in 2025. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 missed. Dividend payments of $0.24 per share continue consistently, supporting income appeal amid mixed analyst sentiment.
Outlook is cautious with 60% hold ratings; consensus target is $18.50 offering ~9% upside. Risks include volatile cash flows from large investing activities and reliance on dividend sustainability. Institutional sentiment is divided, with Zacks rating it Strong Sell on June 23, 2026, contrasting with some bullish dividend coverage analyses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →
